Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Cyclo Therapeutics, Inc. | f8k012715ex99i_ctdholdings.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
January 27, 2015
(Date of earliest event reported)
CTD HOLDINGS, INC.
(Exact Name of Registrant as Specified in Charter)
| Florida | 000-25466 | 59-3029743 | ||
| (State
or Other Jurisdiction of Incorporation) |
(Commission File No.) | (IRS
Employer Identification No.) |
14120 N.W. 126th Terrace Alachua, Florida |
32615 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(386) 418-8060 |
||
| (Registrant’s telephone number, including area code) | ||
Not Applicable |
||
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On January 27, 2015, the Registrant announced that the U.S. Food and Drug Administration (FDA) has accepted its Drug Master File (DMF) submission relating to its second generation Trappsol® Cyclo™ orphan drug product.
A copy of the press release issued by the Registrant relating to the FDA’s acceptance of the Drug Master File submission is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
| 99.1 | Press Release of CTD Holdings, Inc. dated January 27, 2015 |
| - 2 - |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CTD HOLDINGS, INC. | ||
| By: | /s/ Jeffrey L. Tate | |
| Name: | Jeffrey L. Tate | |
| Title: | Chief Executive Officer | |
Date: January 27, 2015
| - 3 - |
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release of CTD Holdings, Inc. dated January 27, 2015 |
- 4 -